^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

VIM expression

i
Other names: VIM, Vimentin, Epididymis Secretory Sperm Binding Protein
Entrez ID:
Related biomarkers:
1d
Antitumor Activity of Selenopsammaplin A Analog (SPA-10091-HCl) via Histone Methyltransferase DOT1L Degradation and Apoptosis Induction in Castration-Resistant Prostate Cancer Cells. (PubMed, Eur J Pharm Sci)
Moreover, SPA-10091-HCl effectively inhibited tumor growth in the PC3 cells-implanted xenograft mouse model without any overt toxicity. These results indicate SPA-10091-HCl as a potential candidate for further development as a chemotherapeutic agent against CRPC.
Journal • PARP Biomarker • IO biomarker • Epigenetic controller
|
BCL2 (B-cell CLL/lymphoma 2) • CDH1 (Cadherin 1) • CASP3 (Caspase 3) • VIM (Vimentin) • CASP9 (Caspase 9) • CDH2 (Cadherin 2) • DOT1L (DOT1 Like Histone Lysine Methyltransferase)
|
CDH1 expression • VIM expression
1d
High MICAL-L2 promotes cancer progression and drug resistance in renal clear cell carcinoma cells through stabilization of ACTN4 following vimentin expression. (PubMed, Biochim Biophys Acta Mol Basis Dis)
Overexpression of MICAL-L2 stimulated cell migration, proliferation, and rendered KIRC cells insensitive to sunitinib and everolimus, two traditional therapies for KIRC. Furthermore, MICAL-L2 overexpression accelerated cancer progression and resistance to therapy in KIRC cells by interacting with its downstream regulator α-actinin-4 (ACTN4) in a Rab13-dependent manner, which reduced the degradation of ACTN4, leading to increased Vimentin expression. All these findings indicate that MICAL-L2 plays a crucial role in the progression of KIRC and suggest that MICAL-L2 may serve as a potential therapeutic target for KIRC treatment.
Journal
|
VIM (Vimentin)
|
VIM expression
|
sunitinib • everolimus
1d
PF-477736 modulates vascular smooth muscle cells phenotypic transition through Chk1/p53/CD44 pathway. (PubMed, Tissue Cell)
Our findings show that PF-477736 exerts anti-vascular remodeling effect by inhibiting phenotypic transition through the Chk1/p53/CD44 pathway in VSMCs, providing novel therapeutic strategies for preventing and treating vascular remodeling.
Journal
|
CD44 (CD44 Molecule) • CHEK1 (Checkpoint kinase 1) • VIM (Vimentin) • PCNA (Proliferating cell nuclear antigen)
|
CD44 expression • VIM expression
|
PF-00477736
1d
Case report: A rare case of renal epithelioid angiosarcoma. (PubMed, Front Oncol)
Immunohistochemistry (IHC) revealed positive expression for CD31, CD10, and vimentin, consistent with the diagnosis of EAS. Although EAS is a rare, aggressive, and often misdiagnosed condition, IHC can help confirm its diagnosis, and in our case, the scattered calcifications observed on CT imaging might be helpful in its differential diagnosis.
Journal
|
VIM (Vimentin) • MME (Membrane Metalloendopeptidase) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
|
CD31 expression • VIM expression
1d
A novel three-dimensional model of Infantile Haemangioma. (PubMed, Br J Dermatol)
The high-throughput application of this 3D angiogenesis model was tested using propranolol to inhibit sprouting of spheroids with increased toxicity response. This study reports the development of a 3D model of IH that recapitulates angiogenic features of IH for molecular analysis and drug screening.
Journal
|
KDR (Kinase insert domain receptor) • VIM (Vimentin) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • SLC2A1 (Solute Carrier Family 2 Member 1)
|
KDR expression • CD44 expression • CD31 expression • VIM expression
1d
Primary sarcomatoid carcinoma of the trachea: A case report and literature review. (PubMed, Medicine (Baltimore))
Pathological morphology and immunohistochemical analyses deepen our understanding of the pathological features of TSC and provide a diagnostic reference for clinicians who will encounter such cases in the future.
Review • Journal
|
VIM (Vimentin)
|
VIM expression
2d
Characterization of Epithelial-Mesenchymal and Neuroendocrine Differentiation States in Pancreatic and Small Cell Ovarian Tumor Cells and Their Modulation by TGF-β1 and BMP-7. (PubMed, Cells)
Likewise, in BIN-67 cells, BMP-7 was able to reduce proliferation, while in SCCOHT-1 cells this occurred only upon combined treatment with TGF-β and BMP-7. We conclude that in PDAC-derived tumor cells, NED is closely linked to EMT and TGF-β signaling, which may have implications for the therapeutic use of TGF-β inhibitors in PDAC management.
Journal • Tumor cell
|
CDH1 (Cadherin 1) • SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2) • VIM (Vimentin) • TGFB1 (Transforming Growth Factor Beta 1) • SSTR5 (Somatostatin Receptor 5) • SNAI1 (Snail Family Transcriptional Repressor 1) • SYP (Synaptophysin) • CHGA (Chromogranin A) • SMAD2 (SMAD Family Member 2) • SMAD3 (SMAD Family Member 3)
|
CDH1 expression • VIM expression
3d
METTL3-Mediated m6A Methylation of USP21 Contributes to Hepatocellular Carcinoma Progression by Stabilizing H2BFS Through Deubiquitination. (PubMed, Biochem Genet)
Further, METTL3-mediated m6A methylation of USP21. METTL3-mediated m6A methylation of USP21 promoted HCC progression by stabilizing H2BFS through deubiquitination.
Journal
|
CDH1 (Cadherin 1) • VIM (Vimentin) • CDH2 (Cadherin 2) • METTL3 (Methyltransferase Like 3)
|
CDH1 expression • VIM expression
3d
Primary Cutaneous Rhabdoid Squamous Cell Carcinoma: A Case Report and Review of Molecular Features. (PubMed, Cureus)
We discuss potential molecular events underlying this transformation. This case highlights the importance of recognizing this rare variant and its implications for patient management and prognosis.
Review • Journal
|
TP53 (Tumor protein P53) • VIM (Vimentin) • KRT5 (Keratin 5)
|
VIM expression
|
DecisionDx®-SCC
6d
HULC-IGF2BP2 Interaction Drives Proliferation and Metastasis in Colorectal Cancer. (PubMed, J Cancer)
HULC promotes CRC cell proliferation, migration, and EMT through its interaction with IGF2BP2, highlighting the critical role of the HULC-IGF2BP2 axis in CRC progression. These findings identify HULC as a potential molecular target for CRC treatment and offer new insights for therapeutic strategies targeting CRC patients.
Journal
|
CDK4 (Cyclin-dependent kinase 4) • VIM (Vimentin) • CDH2 (Cadherin 2) • HULC (Hepatocellular Carcinoma Up-Regulated Long Non-Coding RNA) • IGF2BP2 (Insulin Like Growth Factor 2 MRNA Binding Protein 2)
|
VIM expression
6d
The Role of NDRG1 Expression in Vasculogenic Mimicry of High-grade Gliomas. (PubMed, J Cancer)
There is a trend of correlation between Vimentin expression and MVD in CNSWHO grade 4 HGG patients (P=0.07). NDRG1 exerts adverse effects on the CNSWHO grading of HGG by regulating the expression of VM and MVD in HGG patients, as well as the tumor EMT process.
Journal
|
VIM (Vimentin) • NDRG1 (N-Myc Downstream Regulated 1) • MVD (Mevalonate Diphosphate Decarboxylase)
|
VIM expression
6d
Pathological characterization of lung fibrosis in Sprague-Dawley rats treated with fluoro-edenite fibres by intrapleural injection. (PubMed, J Occup Med Toxicol)
This study confirmed that FE exposure promotes the onset of fibrotic lesions at pleural level, as fibrous plaques or nodules and fibrosis, through a mechanism similar to other form of asbestos. These results combined with epidemiological study reported in Biancavilla residents, corroborate the need to promote health and epidemiological surveillance plans of respiratory diseases in population living in FE contaminated sites.
Preclinical • Journal
|
VIM (Vimentin)
|
VIM expression
11d
Differentiation-inducing factor-1 inhibits EMT by proteasomal degradation of TAZ and YAP in cervical and colon cancer cell lines. (PubMed, Eur J Pharmacol)
These results suggest that DIF-1 inhibits the TAZ/YAP signaling pathway via GSK-3 activation. Further, it has been suggested that the inhibition of EMT induced by DIF-1 is involved with the suppression of TAZ/YAP signaling pathway.
Preclinical • Journal
|
FN1 (Fibronectin 1) • VIM (Vimentin) • TAFAZZIN (Tafazzin)
|
VIM expression
14d
Exosomal miR-20b-5p Induces EMT and Enhances Progression in Non-Small Cell Lung Cancer Via TGFBR2 Downregulation. (PubMed, J Biochem Mol Toxicol)
In vitro and in vivo, exosomes with high levels of miR-20b-5p were linked to the progression of NSCLC. Our data suggest that exosomes with high levels of miR-20b-5p can increase development and metastasis of NSCLC cells by downregulating TGFBR2, which would serve as a predictive and diagnostic marker for NSCLC.
Journal
|
CDH1 (Cadherin 1) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • VIM (Vimentin) • MIR20B (MicroRNA 20b)
|
CDH1 expression • VIM expression • miR-20b-5p expression
15d
Preclinical studies on the antitumor and non-toxic effect of combining pirfenidone with vinorelbine and carboplatin in non-small cell lung cancer. (PubMed, Int J Cancer)
Most interestingly, the triplet treatment exhibited a safer toxicological profile than the doublet (vinorelbine plus carboplatin) currently applied in the clinical practice. Altogether, these preclinical data support the possibility of repurposing pirfenidone in combination with vinorelbine or with vinorelbine plus carboplatin for NSCLC perioperative treatment, improving therapeutic efficacy while reducing toxicity.
Preclinical • Journal
|
VIM (Vimentin)
|
VIM expression
|
carboplatin • vinorelbine tartrate
15d
Blocking CXCR3B Expression Increases Tumor Aggressiveness in Hepatocellular Carcinoma. (PubMed, Anticancer Res)
CXCR3B may play a positive role in suppressing HCC by attenuating natural killer cell cytotoxicity against HCC.
Journal
|
VIM (Vimentin) • CDH2 (Cadherin 2) • SNAI2 (Snail Family Transcriptional Repressor 2) • NKG2D (killer cell lectin like receptor K1)
|
VIM expression
16d
SDC1 Influences Keloid Fibroblasts Migration and Invasion via Targeting Wnt/β-Catenin Signaling Pathway Mediated EMT. (PubMed, J Craniofac Surg)
The results showed that the knockdown of SDC1 markedly suppressed the migration and invasion abilities of keloid fibroblasts and reduced the phenotypes of EMT by inhibiting Wnt/β-catenin signaling pathway. The authors' findings suggest that SDC1 may influences keloid fibroblasts migration and invasion through targeting Wnt/β-catenin signaling pathway mediated EMT, which supports its potential value as a therapeutic target for the treatment of keloid.
Journal
|
CDH1 (Cadherin 1) • SDC1 (Syndecan 1) • VIM (Vimentin) • CDH2 (Cadherin 2)
|
CDH1 expression • VIM expression
16d
Oct4 promotes the progression and radioresistance of esophageal squamous cell carcinoma by regulating epithelial-mesenchymal transition (PubMed, Zhonghua Zhong Liu Za Zhi)
The radiosensitivity was enhanced, with the radiosensitivity enhancement ratio being 1.37±0.11 vs 1.00±0.01 (P=0.037), and after radiotherapy the expression of γ-H2AX increased. Oct4 is involved in the regulation of epithelial-mesenchymal transformation of esophageal squamous cell carcinoma, which promotes the proliferation, migration, and radioresistance of esophageal squamous cell carcinoma.
Journal
|
CDH1 (Cadherin 1) • POU5F1 (POU Class 5 Homeobox 1) • VIM (Vimentin) • CDH2 (Cadherin 2) • ZEB1 (Zinc Finger E-box Binding Homeobox 1) • H2AX (H2A.X Variant Histone) • TCF4 (Transcription Factor 4)
|
CDH1 expression • VIM expression • ZEB1 expression • POU5F1 expression
17d
Jumonji and AT-Rich Interacting Domain 2 (JARID2) exhibits a tumor-suppressive role in Oral Squamous Cell Carcinoma by modulating tumor progression and metastasis. (PubMed, 3 Biotech)
Taken together, the study has confirmed that JARID2 acts as a tumor suppressor, the downregulation of which promotes OSCC progression by regulating Epithelial-to-Mesenchymal Transition (EMT). The online version contains supplementary material available at 10.1007/s13205-024-04163-8.
Journal
|
CDH1 (Cadherin 1) • VIM (Vimentin) • CDH2 (Cadherin 2) • JARID2 (Jumonji And AT-Rich Interaction Domain Containing 2)
|
VIM expression
17d
VIM-AS1, which is regulated by CpG methylation, cooperates with IGF2BP1 to inhibit tumor aggressiveness via EPHA3 degradation in hepatocellular carcinoma. (PubMed, Exp Mol Med)
In vivo experiments further confirmed that the VIM-AS1‒EPHA3 axis controlled tumor growth and the tumor microenvironment in HCC. These findings suggest that the downregulation of VIM-AS1 due to hypermethylation at cg02746869 increased EPHA3 mRNA expression via a m6A-dependent mechanism to increase HCC aggressiveness.
Journal
|
VIM (Vimentin) • EPHA3 (EPH receptor A3) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • VIM-AS1 (VIM Antisense RNA 1)
|
VIM expression
17d
Nanaomycin K Inhibited Cell Proliferation and Epithelial-Mesenchymal Transition in Renal Cell Carcinoma. (PubMed, Biol Pharm Bull)
Intratumor administration of nanaomycin K significantly inhibited tumor growth without apparent adverse events for mice. These results indicate that nanaomycin K inhibit cell growth and EMT in TGF-β-induced advanced RCC, and that nanaomycin K is a potential candidate for the treatment of RCC.
Journal
|
CDH1 (Cadherin 1) • CASP3 (Caspase 3) • VIM (Vimentin) • CASP8 (Caspase 8) • TGFB1 (Transforming Growth Factor Beta 1) • CASP9 (Caspase 9) • CDH2 (Cadherin 2) • SNAI2 (Snail Family Transcriptional Repressor 2)
|
CDH1 expression • VIM expression
19d
Withaferin-A induced Vimentin S56 phosphorylation dissociates NEDD9 signaling loop to regress progressive metastatic melanoma into lung adenocarcinoma. (PubMed, Chem Biol Interact)
The investigation emphasized more mechanistic approach of WFA. Understanding and targeting such integrative mechanical input in the tumor microenvironment will be a better therapeutic strategy to combat metastasis.
Journal • Metastases
|
CDH1 (Cadherin 1) • MMP2 (Matrix metallopeptidase 2) • VIM (Vimentin) • CDH2 (Cadherin 2) • MMP9 (Matrix metallopeptidase 9)
|
VIM expression
20d
METTL3 and HERC4: Elevated Expression and Impact on Hepatocellular Carcinoma Progression. (PubMed, Cancer Biother Radiopharm)
Besides, HERC4 overexpression reversed the effects of METTL3 silencing on the proliferation and migration as well as the levels of angiogenic factors in HCC cells. This study reveals the upregulation of METTL3 and HERC4 expression in HCC and their role in HCC by enhancing the proliferation, migration, and angiogenesis potential of HCC cells.
Journal
|
VIM (Vimentin) • FGF (Fibroblast Growth Factor) • CDH2 (Cadherin 2) • METTL3 (Methyltransferase Like 3) • UBR5 (Ubiquitin Protein Ligase E3 Component N-Recognin 5)
|
VIM expression • ERBB4 expression
20d
Effect of silencing Ras homolog family member C on proliferation, invasion, and migration of salivary adenoid cystic carcinoma. (PubMed, Hua Xi Kou Qiang Yi Xue Za Zhi)
RhoC is highly expressed in SACC, and RhoC silencing may target the downstream ROCK1/p38MAPK/TWIST1 signaling pathway, thereby inhibiting the proliferation, invasion, migration, and EMT of SACC while promoting its apoptosis. On the contrary, miR-138-5p is lowly expressed in SACC and is a potential upstream gene of RhoC, and there may be binding sites between the two genes.
Journal
|
CDH1 (Cadherin 1) • VIM (Vimentin) • CDH2 (Cadherin 2) • TWIST1 (Twist Family BHLH Transcription Factor 1) • MIR138 (MicroRNA 138) • ROCK1 (Rho Associated Coiled-Coil Containing Protein Kinase 1)
|
CDH1 expression • VIM expression
21d
Vascular endothelial growth factor facilitates the effects of telocytes on tumor cell proliferation and migration. (PubMed, Front Cell Dev Biol)
Notably, these effects were inhibited by the addition of bevacizumab. In conclusion, our findings illuminated the role of telocytes in promoting tumor progression, and confirmed their crucial regulatory role in the growth of tumor cells.
Journal • Tumor cell
|
VEGFA (Vascular endothelial growth factor A) • CDH1 (Cadherin 1) • VIM (Vimentin)
|
CDH1 expression • VIM expression
|
Avastin (bevacizumab)
23d
Malignant Mixed Mullerian Tumor (Carcinosarcoma) in the Female Genital Tract: A Retrospective Study From a Single Center in North India. (PubMed, Cureus)
Clinical and histological features resemble high-grade endometrial carcinoma, necessitating an extensive IHC panel to narrow down differentials and confirm the diagnosis. This study highlights the histological and IHC features and emphasizes that early diagnosis plays a crucial role in disease management.
Retrospective data • Journal
|
VIM (Vimentin)
|
VIM expression
27d
Inhibition of miR-20a-5p Suppresses Epithelial-Mesenchymal Transition of Colorectal Cancer Cells Through GJA1. (PubMed, Mol Biotechnol)
miR-20a-5p inhibitor + sh-GJA1 promoted the invasion, migration, and proliferation of colon cancer cells and EMT process. Overall, miR-20a-5p could target GJA1 to down-regulate the GJA1 expression, thereby regulating the EMT response, and ultimately promoting the progression of colorectal cancer.
Journal
|
CDH1 (Cadherin 1) • VIM (Vimentin) • CDH2 (Cadherin 2) • GJA1 (Gap Junction Protein Alpha 1) • MIR20A (MicroRNA 20a)
|
CDH1 expression • VIM expression • GJA1 expression
28d
Altingia chinensis petroleum ether extract suppresses NSCLC via induction of apoptosis, attenuation of EMT, and downregulation of PI3K/Akt pathway. (PubMed, Phytomedicine)
Overall, APE exhibits anti-tumor effects on NSCLC via induction of apoptosis, attenuation of EMT, and its mechanism involves the suppression of the PI3K/Akt pathway. Our study offers new insights for the identification of novel drug development for NSCLC.
Journal • IO biomarker
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BCL2 (B-cell CLL/lymphoma 2) • CDH1 (Cadherin 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • VIM (Vimentin) • ANXA5 (Annexin A5)
|
CDH1 expression • VIM expression
30d
Prognostic value of EMT-related genes and immune cell infiltration in thyroid carcinoma. (PubMed, Front Immunol)
Furthermore, in vitro studies demonstrated that reducing CTSK expression led to significant reductions in THCA cell viability; clonogenic, proliferative, motility and migratory capacities; and the expression of key EMT-related proteins, including N-cadherin, vimentin, slug, and snail. Our results suggest that the expression of CTSK, a gene associated with the EMT, may be associated with THCA onset and progression and thus may serve as a promising prognostic biomarker.
Journal • Immune cell
|
VIM (Vimentin) • CDH2 (Cadherin 2) • CTSK (Cathepsin K) • SNAI2 (Snail Family Transcriptional Repressor 2)
|
VIM expression
1m
FXR deficiency induced ferroptosis via modulation of the CBP-dependent p53 acetylation to suppress breast cancer growth and metastasis. (PubMed, Cell Death Dis)
In conclusion, the FXR was first reported as a tumor promoter that enhanced the proliferation and metastasis of breast cancer cells through regulating CBP-dependent p53 K382 acetylation. It proposes that FXR may serve as a potential therapeutic target for the treatment of breast cancer.
Journal
|
CREBBP (CREB binding protein) • VIM (Vimentin) • TGFB1 (Transforming Growth Factor Beta 1) • SLC7A11 (Solute Carrier Family 7 Member 11)
|
SLC7A11 expression • VIM expression
1m
Molecular mechanisms restoring olaparib efficacy through ATR/CHK1 pathway inhibition in olaparib-resistant BRCA1/2MUT ovarian Cancer models. (PubMed, Biochim Biophys Acta Mol Basis Dis)
Olaparib-resistant xenografts were treated with olaparib, ATR inhibitor (ATRi, ceralasertib), CHK1 inhibitor (CHK1i, MK-8776) or their combinations. Our collective findings indicate that ATR/CHK1 pathway inhibition restores the olaparib efficacy in resistant BRCA1/2MUT high-grade serous OC, highlighting promising approach for olaparib rechallenge of non-responsive patients. Uncovered mechanisms might improve our understanding of acquisition and overcoming resistance to olaparib in ovarian cancer.
Preclinical • Journal • BRCA Biomarker • PARP Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • VIM (Vimentin) • TP53BP1 (Tumor Protein P53 Binding Protein 1)
|
BRCA2 mutation • BRCA1 mutation • VIM expression
|
Lynparza (olaparib) • ceralasertib (AZD6738) • MK-8776
1m
Clear cell stromal tumor of the lung: Report of 3 cases with emphasis on multifocal tumors. (PubMed, Pathol Res Pract)
These cases highlight the existence of multifocal pulmonary CCST and seem to support the notion that multifocality in CCST may be associated with more protracted clinical course. Awareness of the existence of multifocal pattern is important for patient management and prognosis.
Journal • Stroma
|
YAP1 (Yes associated protein 1) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • VIM (Vimentin)
|
VIM expression • TFE3 fusion
1m
Perinuclear assembly of vimentin intermediate filaments induces cancer cell nuclear dysmorphia. (PubMed, J Biol Chem)
Moreover, we found that VIF-mediated nuclear dysmorphia led to defects in DNA repair. Together, our results unveil a novel role of VIFs in cancer cell nuclear dysmorphia, which is associated with genome instability.
Journal
|
VIM (Vimentin) • TGFB1 (Transforming Growth Factor Beta 1)
|
VIM expression
1m
Farrerol suppresses epithelial-mesenchymal transition in hepatocellular carcinoma via suppression of TGF-β1/Smad2/3 signaling. (PubMed, Pathol Res Pract)
Overall, farrerol suppresss HCC by inhibiting migration, invasiveness, the EMT, and angiogenesis, implying that farrerol could be a promising antimetastasis agent for HCC.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • CDH1 (Cadherin 1) • VIM (Vimentin) • TGFB1 (Transforming Growth Factor Beta 1) • CDH2 (Cadherin 2) • SNAI2 (Snail Family Transcriptional Repressor 2) • ZEB1 (Zinc Finger E-box Binding Homeobox 1)
|
VIM expression
1m
Euphorbia helioscopia inhibits proliferation, invasion, and migration and promotes apoptosis of non-small cell lung cancer cells (PubMed, Nan Fang Yi Ke Da Xue Xue Bao)
Euphorbia helioscopia can inhibit proliferation, invasion, and migration and induces apoptosis of NSCLC cells in vitro.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CDH1 (Cadherin 1) • MMP2 (Matrix metallopeptidase 2) • BAX (BCL2-associated X protein) • VIM (Vimentin) • MMP9 (Matrix metallopeptidase 9)
|
BCL2 expression • CDH1 expression • BAX expression • VIM expression
|
cisplatin
1m
Aumolertinib combined with anlotinib inhibits proliferation of non-small cell lung cancer cells by down-regulating the PI3K/AKT pathway (PubMed, Nan Fang Yi Ke Da Xue Xue Bao)
Aumolertinib combined with anlotinib can effectively inhibit NSCLC cell proliferation by downregulating the PI3K-Akt pathway, suggesting a potentially new option for NSCLC treatment.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CDH1 (Cadherin 1) • MMP2 (Matrix metallopeptidase 2) • BAX (BCL2-associated X protein) • VIM (Vimentin) • MMP9 (Matrix metallopeptidase 9)
|
BCL2 expression • CDH1 expression • BAX expression • VIM expression
|
Focus V (anlotinib) • Ameile (aumolertinib)
1m
Cisplatin promotes TNF-α autocrine to trigger RIP1/RIP3/MLKL-dependent necroptosis of human head and neck squamous cell carcinoma cells (PubMed, Nan Fang Yi Ke Da Xue Xue Bao)
Cisplatin activates nuclear factor-κB signaling in HNSCCs to promote TNF-α autocrine and induce RIP1/RIP3/MLKL-dependent necroptosis, thus leading to inhibition of cell proliferation.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • CDH1 (Cadherin 1) • VIM (Vimentin) • CASP8 (Caspase 8) • CDH2 (Cadherin 2) • RIPK1 (Receptor Interacting Serine/Threonine Kinase 1) • RELA (RELA Proto-Oncogene)
|
CDH1 expression • VIM expression
|
cisplatin
1m
GATA3 Expression in Solid Vimentin-Negative Eosinophilic Renal Epithelial Tumors-A Comprehensive Study of 48 Tumors. (PubMed, Int J Surg Pathol)
Therefore, GATA3 could be useful as a panel of immunohistochemical stains that are used in diagnostic algorithm of vimentin-negative solid eosinophilic renal tumors. However, one should not solely rely on GATA3 as vimentin-negative solid eosinophilic renal tumors can have overlapping GATA3 expression.
Journal
|
VIM (Vimentin) • FLCN (Folliculin) • GATA3 (GATA binding protein 3)
|
VIM expression • FLCN mutation
1m
Network pharmacology combined with transcriptomics reveals that formononetin, a biologically component of Astragalus membranaceus (Fisch.) Bunge, inhibits the PI3K/AKT signaling pathway to improve chronic renal failure. (PubMed, J Ethnopharmacol)
FMN treatment significantly reduced the release of inflammatory cytokines and inhibited the effects of the PI3K/Akt signaling pathway on the key targets IL-4 and NOS3. Our results suggest FMN therapy as a novel therapeutic strategy for treating CRF.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CDH1 (Cadherin 1) • FN1 (Fibronectin 1) • VIM (Vimentin) • TGFB1 (Transforming Growth Factor Beta 1) • CDH2 (Cadherin 2) • IL1B (Interleukin 1, beta) • IL4 (Interleukin 4) • NOS3 (Nitric oxide synthase 3)
|
CDH1 expression • VIM expression
1m
Loss of vimentin expression in preoperative biopsies independently predicts poor prognosis, lymph node metastasis and recurrence in endometrial cancer. (PubMed, BJC Rep)
Loss of vimentin in preoperative biopsies serves as an independent predictor of poor prognosis and lymph node metastases. Incorporating vimentin as a clinical marker can improve risk stratification and treatment decisions.
Journal • Biopsy
|
VIM (Vimentin)
|
VIM expression
1m
Effect of phosphorylated HSP27 on the proliferation and metastasis of nasopharyngeal carcinoma and its mechanism (PubMed, Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi)
As p-HSP27 plays different roles in different stages of nasopharyngeal carcinoma metastasis, it can increase the migration ability of CNE2 cells and reduce its invasion ability. p-HSP27 may induce EMT changes in CNE2 by down-regulating E-cadherin, thus promoting CNE2 migration, and may inhibit CNE2 invasion by down-regulating MMPs expression.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • CDH1 (Cadherin 1) • MMP2 (Matrix metallopeptidase 2) • BAX (BCL2-associated X protein) • VIM (Vimentin) • MMP9 (Matrix metallopeptidase 9)
|
BCL2 expression • CCND1 expression • CDH1 expression • BAX expression • VIM expression
1m
Fluorescence-guided tumor visualization of colorectal cancer using tumor-initiating probe yellow in preclinical models. (PubMed, Sci Rep)
Altogether, these results demonstrated that TiY has a strong potential for visualizing CRC by fluorescence imaging in various preclinical models, which can be further translated for clinical use such as fluorescence-guided surgery. Furthermore, our data indicate that TiY is preferentially uptaken by cells with EMT induction and progression, and overexpressing vimentin and Zeb1 in patients with CRC.
Preclinical • Journal
|
VIM (Vimentin) • ZEB1 (Zinc Finger E-box Binding Homeobox 1)
|
VIM expression • ZEB1 expression